Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

Central Versus Peripheral GABA and Glutamate Biomarkers for Treatment Response During Two Infusions of Intravenous Ketamine for Treatment-Resistant Depression

To see complete record on, please visit this link

Id: NCT03573349

Organisation Name: Mayo Clinic

Overal Status: Enrolling by invitation

Start Date: January 3, 2019

Last Update: September 14, 2022

Lead Sponsor: Mayo Clinic

Brief Summary: This is a feasibility study and the goal of this project is to evaluate whether peak ACC GABA and glutamate, quantified as a CSF-corrected absolute concentration percent change from baseline, is associated with clinical remission, Montgomery Asberg Depression Rating Scale (MADRS) total score of <10, to the anti-glutamatergic antidepressant ketamine.

As MRS is expensive, we also aim to study a correlation between change in peripheral metabolites (GABA and glutamate) and central GABA and glutamate levels.

  • Major Depressive Disorder
  • Treatment Resistant Depression
  • Bipolar Depression

Total execution time in seconds: 0.21261382102966